Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

Discover why analysts are bullish on Arcutis Biotherapeutics after strong Q3 results, despite recent market fluctuations in ...

Our expanding ZORYVE portfolio now encompasses psoriasis, seborrheic dermatitis, and atopic dermatitis ... and the ripple ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Atopic dermatitis, also known as atopic eczema, is a chronic inflammatory familial disease of the skin. It is characterized by an increased ability to form immunoglobulin E and a tendency to ...

cream, 1% as a treatment for atopic dermatitis (AD) in adults and children two years of age and older. The new target date is March 12, 2025, revised from the original target action date of December ...

cream, 1% as a treatment for atopic dermatitis (AD) in adults and children two years of age and older. The new target date is March 12, 2025, revised from the original target action date of ...

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older Organon (NYSE: OGN), a global healthcare company with a ...

The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the ...

Seborrheic dermatitis, a common skin condition ... However, some users may not like the tea tree scent, which can be quite strong. Additionally, while the shampoo works well for many people ...